Densidade mineral ossea em pacientes com lupus eritematoso sistemico e sua relação com niveis estrogenos

AUTOR(ES)
DATA DE PUBLICAÇÃO

1998

RESUMO

The objectives of this study were: 1) to evaluate bone mineral density ( BMD ) in premenopausal patients with systemic lupus erythematosus ( SLE ); 2) to determine the role of corticosteroids and citotoxic drugs and 3) to assess estrogen effect on BMD in SLE. BMD was measured by dual energy x-ray absorptiometry at lumbar vertebrae ( L2-L4 ) and at femoral neck in 60 premonopausal patients with SLE and in 64 normal women. Serum concentrations of estradiol were measured by radioimmunoassay ( RIA ). Age, age at the disease onset, body mass index ( BMI ), time of disease, disease activity ( SLEDAI ), total cumulative prednisone dose, prednisone dose at the evaluation and cumulative prednisone dose in the last year before evaluation were also assessed. The mean age was 32,87 among patients and 31,16 among the control group. The mean serum concentrations of estradiol was 175,98 pg/ml in the patients group and 149,9 in the controls. BMD was inferior in patients than in controls and the difference was statisticaly significant. The mean prednisone dose at evaluation was 19,17 mg per day, while the mean cumulative prednisone dose was 28,78 g. The last year cumulative dose of prednisone was 5,33 g. There was no association neither with corticosteroids doses and loss of bone mass, nor with citotoxic drug used. No association was found with the other variables disease related analysed. The serum concentrations of estradiol did not influence the bone mass loss. The body mass index and the age at the disease onset showed influence on BMD at L2. In conclusion, BMD was significantly low in patients with SLE than in ~ontrols; there was no association with CE or other drugs and loss of bone mass in patients with SLE; the estradiol had no effect on BMD in these patients and low bone mass index interacting with early onset of diseasemight influence the probability ofloss ofbone mass.

ASSUNTO(S)

doenças auto-imunes osteoporose

ACESSO AO ARTIGO

Documentos Relacionados